{"id":606,"date":"2014-07-21T14:23:15","date_gmt":"2014-07-21T18:23:15","guid":{"rendered":"http:\/\/blogstemp3.wpengine.com\/?p=606"},"modified":"2014-07-21T14:23:15","modified_gmt":"2014-07-21T18:23:15","slug":"hepatitis-c-virus-infection-how-are-you-managing-the-cost-of-newer-treatments","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/hepatitis-c-virus-infection-how-are-you-managing-the-cost-of-newer-treatments\/2014\/07\/21\/","title":{"rendered":"Hepatitis C Virus Infection: How Are You Managing the Cost of Newer Treatments?"},"content":{"rendered":"<p>Recently, we have seen remarkable progress in the treatment of chronic infection with hepatitis C virus \u2014 from long courses of injectable interferon plus ribavirin to short courses of once-daily oral sofosbuvir. Not only have these shorter, more-manageable regimens proven more effective, they are substantially better tolerated. So, what\u2019s the problem? It seems to be the price tag!<\/p>\n<p>Treating chronic HCV infection has never been cheap, but some of the newer treatments now cost over $80,000, and payers and patients are balking at the cost. Moreover, newer agents that may or may not be less costly will become available within the next year or so.<\/p>\n<p>So, I am curious to hear from you on the following:<\/p>\n<ul>\n<li>What is your first-line regimen for most of your HCV-infected patients?<\/li>\n<li>Do you use more than one therapy depending on genotype, viral load, and liver histology?<\/li>\n<li>Are you running into barriers from payers in using your first choice? If so, how do you appeal, and what has been your success with appeals?<\/li>\n<li>Are you waiting for newer treatment options with the hope that the cost will come down?<\/li>\n<li>What are your patients telling you about this issue?<\/li>\n<\/ul>\n<p>I\u2019m looking forward to hearing from you on this topic.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Recently, we have seen remarkable progress in the treatment of chronic infection with hepatitis C virus \u2014 from long courses of injectable interferon plus ribavirin to short courses of once-daily oral sofosbuvir. Not only have these shorter, more-manageable regimens proven more effective, they are substantially better tolerated. So, what\u2019s the problem? It seems to be [&hellip;]<\/p>\n","protected":false},"author":29,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,10,13,15,1],"tags":[],"class_list":["post-606","post","type-post","status-publish","format-standard","hentry","category-drugs","category-hepatology","category-patient-care","category-practice-environment","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts\/606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/comments?post=606"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts\/606\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/media?parent=606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/categories?post=606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/tags?post=606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}